Skip to main content

Table 3 Comparison of the laboratory results of patients with EGC between the delayed bleeding group and the nonbleeding group

From: External validation of the BEST-J score and a new risk prediction model for ESD delayed bleeding in patients with early gastric cancer

  Nonbleeding group (n = 417) Delayed bleeding group (n = 27) P value
Hemoglobin value [n (%)]   0.061
 ≥ 90 g/L 417 (100.0) 26 (96.3)  
 < 90 g/L 0 (0.0) 1 (3.7)  
Platelet value [n (%)]   1.000
 ≥ 125 × 109/L 389 (93.3) 26 (96.3)  
 < 125 × 109/L 28 (6.7) 1 (3.7)  
PT [n (%)]    0.397
 ≤ 13.5 s 410 (98.3) 26 (96.3)  
 > 13.5 s 7 (1.7) 1 (3.7)  
PT(A) [n (%)]    0.650
 ≥ 80% 395 (94.7) 25 (92.6)  
 < 80% 22 (5.3) 2 (7.4)  
INR [n (%)]    0.315
 ≤ 1.2 412 (98.8) 26 (96.3)  
 > 1.2 5 (1.2) 1 (3.7)  
Prolongation of APTT [n (%)]   0.009*
 No 406 (97.4) 23 (85.2)  
 Yes 11 (2.6) 4 (14.8)  
  1. APTT, activated partial thromboplastin time; EGC, early gastric cancer; INR, international standardized ratio; PT, prothrombin time; PT(A), prothrombin time activity
  2. *P < 0.05